Kestra Private Wealth Services LLC Sells 1,820 Shares of Koninklijke Philips (NYSE:PHG)

Kestra Private Wealth Services LLC trimmed its holdings in Koninklijke Philips (NYSE:PHG) by 9.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,776 shares of the technology company’s stock after selling 1,820 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Koninklijke Philips were worth $415,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Capital Analysts LLC raised its stake in shares of Koninklijke Philips by 6.3% in the fourth quarter. Capital Analysts LLC now owns 8,820 shares of the technology company’s stock valued at $206,000 after purchasing an additional 521 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in shares of Koninklijke Philips by 3.2% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 22,616 shares of the technology company’s stock valued at $451,000 after purchasing an additional 696 shares in the last quarter. Kovitz Investment Group Partners LLC raised its stake in shares of Koninklijke Philips by 1.7% in the third quarter. Kovitz Investment Group Partners LLC now owns 44,746 shares of the technology company’s stock valued at $892,000 after purchasing an additional 750 shares in the last quarter. Bank of New Hampshire raised its stake in shares of Koninklijke Philips by 0.8% in the fourth quarter. Bank of New Hampshire now owns 117,280 shares of the technology company’s stock valued at $2,736,000 after purchasing an additional 908 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its stake in shares of Koninklijke Philips by 7.4% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 13,619 shares of the technology company’s stock valued at $318,000 after purchasing an additional 940 shares in the last quarter. 13.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PHG has been the subject of a number of recent research reports. JPMorgan Chase & Co. upgraded Koninklijke Philips from an “underweight” rating to a “neutral” rating in a research note on Tuesday, April 30th. BNP Paribas lowered Koninklijke Philips from an “outperform” rating to an “underperform” rating in a research note on Wednesday, February 7th. UBS Group upgraded Koninklijke Philips from a “sell” rating to a “neutral” rating in a research note on Tuesday, April 30th. Finally, StockNews.com upgraded Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Koninklijke Philips presently has an average rating of “Hold” and a consensus target price of $19.00.

Koninklijke Philips Price Performance

Koninklijke Philips stock opened at $26.90 on Tuesday. Koninklijke Philips has a 52-week low of $17.75 and a 52-week high of $29.44. The company has a current ratio of 1.20, a quick ratio of 0.78 and a debt-to-equity ratio of 0.58. The stock has a fifty day moving average price of $21.22 and a two-hundred day moving average price of $21.27.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.